MELBOURNE, Australia, Oct. 10, 2023 /PRNewswire/ — UsabilityHub, a leading provider of user experience software, has unveiled a new name, new brand identity, and increased feature set as part of an extensive rebranding initiative.
In 2008, UsabilityHub started as a simple five second test. Led by co-founders Mateja Milosavljevic, Tristan Gamlis, and Nicholas Firth-McCoy, it has since expanded to offer a wide range of usability testing methodologies, boasts a vast participant panel, and has recently added interview studies to its offering. Today, over 320,000 designers, marketers, product leaders, and researchers, use the platform to deeply understand their audience and move in the right direction — faster.
UsabilityHub rebrands to Lyssna. (L-R) Co-founders Tristan Gamlis, Mateja Milosavljevic (CEO) and Nicholas Firth-McCoy
The company cited recent product expansion and a broader vision for the reason behind the change. The new name, Lyssna, means ‘to listen’ in Swedish. The company sees listening as the foundation of human connection and understanding, and therefore at the heart of their experience research mission.
"I couldn’t be more excited about this new chapter in our fifteen-year history. Lyssna is more than just a name, it’s a commitment to listen, evolve, and be the best platform for conducting experience research." — Mateja Milosavljevic, CEO, Lyssna
Lyssna’s experience research platform and extensive research panel helps to put people at the heart of solutions to improve the quality of experiences in the world. Their focus is on human connection and facilitating this in an accessible, iterative, and agile way so that solutions can meet the specific needs, contexts, and behaviors of end-users. Whether that’s by providing software solutions allowing companies to conduct this research with their own end-users, or by providing access to end-users for companies who don’t have their own audience to test with.
"We’re able to get real feedback from customers and remove friction during the testing process." — Nadav Hachamov, UX Researcher at monday.com
Lyssna boasts an impressive portfolio of brands utilizing its solution including monday.com, Klarna, Zendesk, Hilton, Loreal, GoDaddy, and more. With a view to democratizing research, they offer free plans up to enterprise level.
"I’m delighted to bring the Lyssna brand to life. It’s an exciting step forward in our growth journey. Our broader vision is the start of a new phase for our brand and product." — Claire Brown, Director of Marketing, Lyssna
The company continues to lead the way in customer support and satisfaction, boasting 4.5 out of 5 stars on G2 and taking the leader position in the user research category for Fall 2023.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
SHANGHAI, Oct. 10, 2023 /PRNewswire/ — SMIC’s third quarter 2023 results will be released on the Hong Kong Stock Exchange website (https://www.hkex.com.hk) and Shanghai Stock Exchange website (http://www.sse.com.cn) after the close of trading on Thursday, November 9, 2023.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
DUBLIN, Oct. 10, 2023 /PRNewswire/ — EnigmaSoft Limited, a company focused on providing robust anti-malware solutions, has released SpyHunter Web Security – a FREE browser extension that helps users block dangerous sites and web-based threats. SpyHunter Web Security offers enhanced protection against online security risks. SpyHunter Web Security seamlessly integrates with popular web browsers and alerts users about potentially harmful websites before they are opened.
SpyHunter Web Security seamlessly integrates with popular web browsers and alerts users about potentially harmful websites before they are opened.
Increase Security by Blocking & Avoiding Dangerous Websites
SpyHunter Web Security is a free standalone browser extension that functions independently from other EnigmaSoft products. EnigmaSoft also offers SpyHunter 5 and SpyHunter for Mac, which are complete desktop solutions that provide comprehensive protection against malware and other threats. To detect and remove malware for FREE, go to https://www.enigmasoftware.com/products/spyhunter/.
SpyHunter Web Security Improves Your Online Privacy & Security
Block Unsafe Websites SpyHunter Web Security blocks websites categorized as potentially unsafe. SpyHunter Web Security operates at the browser level and automatically scans links in emails and documents, plus addresses you manually enter before they are opened.
Search Engine Integration SpyHunter Web Security integrates with Google, Bing, and other popular search engines to screen your search results. SpyHunter Web Security displays icons next to search results to help protect you against potentially unsafe websites.
Allow Trusted Websites Where SpyHunter Web Security might identify a website you trust, SpyHunter Web Security allows users the choice to override the detection and proceed to the website.
Want to Become an Affiliate and Promote SpyHunter for 55% Payout?
EnigmaSoft Limited is a privately held Irish company with offices and global headquarters in Dublin, Ireland. EnigmaSoft is best known for developing and distributing SpyHunter. SpyHunter detects and removes malware and enhances Internet privacy. SpyHunter 5 has scored top grades in comparative testing by independent third-party testing labs such as AV-TEST. SpyHunter 5 has also been certified by AppEsteem and TRUSTe.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
BlackBerry UEM and ServiceNow Flow Designer integrations enable IT admins to automate a variety of otherwise manual device management tasks
WATERLOO, ON, Oct. 10, 2023 /PRNewswire/ — BlackBerry Limited (NYSE: BB; TSX: BB) today announced they have partnered with leading digital workflow company, ServiceNow, to automate device management for organizations. The solution, which integrates ServiceNow’s Flow Designer and BlackBerry® UEM, will help reduce administrative burdens on IT teams across the most frequently leveraged device management tasks while maintaining the highest levels of security.
Available now in the ServiceNow Store, the new, certified integration automates tasks including user activations, policy configurations, device commands, and more. IT teams will be able to customize the UEM actions they would like to automate for a solution that is tailored to their organization.
"We are delighted to partner with ServiceNow and enable organizations to automate their IT operations," said Neelam Sandhu, Chief Elite Customer Success Officer, BlackBerry. "BlackBerry UEM and ServiceNow’s Flow Designer are trusted around the world and across industries. This new integration will enable our customers to reimagine digital workplace productivity while continuing to enjoy the highest security posture."
"ServiceNow is pleased to welcome BlackBerry UEM to the ServiceNow Store," said Nick Tzitzon, Chief Strategy and Corporate Affairs Officer at ServiceNow. "BlackBerry’s commitment to technology innovation and enterprise security is aligned with ServiceNow’s. This partnership holds significant potential for our customers."
BlackBerry pioneered the enterprise mobility management industry. Today the company’s solution holds the most security certifications in the industry and is the only UEM to be named 2023 Customers Choice by Gartner® Peer Insights™. For more information on BlackBerry UEM visit BlackBerry.com/UEM.
ServiceNow’s Flow Designer enables businesses to create end-to-end digital workflows to automate operations and improve efficiency and experience. For more information on ServiceNow Flow Designer click here.
For more information on the new solution from ServiceNow and BlackBerry visit the BlackBerry blog, register for BlackBerry Summit, taking place on October 17, where speakers from industry, enterprise and BlackBerry will reveal the future of IoT, IT and Cybersecurity and showcase the latest BlackBerry innovations, and attend the Live on ServiceNow Welcome Webinar on October 24.
About BlackBerry BlackBerry (NYSE: BB; TSX: BB) provides intelligent security software and services to enterprises and governments around the world. The company secures more than 500M endpoints including over 235M vehicles. Based in Waterloo, Ontario, the company leverages AI and machine learning to deliver innovative solutions in the areas of cybersecurity, safety, and data privacy solutions, and is a leader in the areas of endpoint security, endpoint management, encryption, and embedded systems. BlackBerry’s vision is clear – to secure a connected future you can trust.
For more information, visit BlackBerry.com and follow @BlackBerry.
Trademarks, including but not limited to BLACKBERRY and EMBLEM Design are the trademarks or registered trademarks of BlackBerry Limited, and the exclusive rights to such trademarks are expressly reserved. All other trademarks are the property of their respective owners. BlackBerry is not responsible for any third-party products or services.
ServiceNow, the ServiceNow logo, Now, Now Platform, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries.
Media Contact: BlackBerry Media Relations +1 (519) 597-7273 [email protected]
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
– Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached
– Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039
ROCKVILLE, Md. and SHANGHAI, Oct. 10, 2023 /PRNewswire/ — I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced multiple recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio (Kosdaq: 298380). TJ-L14B/ABL503 is designed to address tumors resistant to PD-(L)1 antibodies through its unique ability to conditionally activate 4-1BB upon binding to its target, PD-L1. I-Mab owns 50% of the global rights of TJ-L14B/ABL503.
On September 7, 2023, TJ-L14B/ABL503 successfully obtained patent registration in eight Eurasian countries. The patent, officially named "Anti-PD-L1/Anti-4-1BB Bispecific Antibody and Its Applications," secures patent rights extending through 2039. Furthermore, this patent has already been granted in Chile, South Africa, and Japan. Patent examinations are currently underway in over 20 countries, including the U.S., China, and Europe.
TJ-L14B/ABL503 is currently being investigated in a Phase 1 dose-escalation study in patients with progressive, locally advanced or metastatic solid tumors who are relapsed or refractory following prior lines of treatment. The dose-expansion portion of the Phase 1 study is actively progressing in the U.S. and South Korea. Currently, we have observed 1 complete response (CR), 1 partial response (PR), and 2 patients who achieved an unconfirmed objective response upon recent enrollment. While preliminary efficacy signals have emerged, the maximum tolerated dose (MTD) has not yet been reached. The Company anticipates presenting the top-line Phase 1 clinical data at a major medical conference in the first half of 2024.
"We’re encouraged by these early results of TJ-L14B/ABL503 as they continue to demonstrate the potential of this highly differentiated treatment for tumor types with significant unmet need," said Raj Kannan, CEO of I-Mab. "With the success of patent registrations across multiple countries, and promising preliminary data from the Phase 1 study, we’re reaffirming the possibility for TJ-L14B/ABL503 to make a significant impact on the lives of people with cancer. We look forward to sharing more progress on the global development of TJ-L14B/ABL503."
"The clinical responses observed in the Phase 1 clinical study of TJ-L14B/ABL503, though in early stages, not only provide validation of our technology platform but also offer proof of the mechanism behind this innovative bispecific antibody," said Sanghoon Lee, CEO of ABL Bio. "We express our heartfelt gratitude to the patients who participated in the study, healthcare professionals, study investigators, and our partners for their invaluable collaboration in achieving this milestone. Concurrently, we are expediting patent filings for TJ-L14B/ABL503 to safeguard its rights and facilitate its seamless entry into the global market."
About TJ-L14B/ABL503
Being developed jointly with ABL Bio (Kosdaq: 298380, hereafter "ABL"), TJ-L14B/ABL503 is a differentiated PD-L1-based bispecific antibody with the PD-L1 arm as the tumor-dependent T-cell activator and the 4-1BB arm as the conditional T cell activator upon tumor engagement. Using ABL’s "Grabody-T" bispecific antibody platform technology, TJ-L14B/ABL503 stimulates 4-1BB activation only in the presence of PD-L1 expressing tumor cells to minimize the risk of off-tumor toxicity. Preclinical studies have demonstrated that the bispecific antibody shows better anti-tumor activity than equimolar doses of single agents alone or in combination. A Phase 1 study is currently being conducted in the U.S. and South Korea.
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab’s innovative pipeline is driven by internal R&D’s Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn, Twitter, and WeChat.
I-Mab Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from clinical studies of TJ-L14B/ABL503, the potential implications of clinical data for patients, and I-Mab’s advancement of, and anticipated clinical development, regulatory milestones, and commercialization of TJ-L14B/ABL503. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to I-Mab’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab’s drug candidates; I-Mab’s ability to achieve commercial success for its drug candidates, if approved; I-Mab’s ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab’s reliance on third parties to conduct drug development, manufacturing and other services; I-Mab’s limited operating history and I-Mab’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab’s most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab’s subsequent filings with the US Securities and Exchange Commission. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
This initiative sees Lalamove calling for users in Asia and Latin America to support 10 animal shelters by donating loyalty points
HONG KONG, Oct. 10, 2023 /PRNewswire/ — Lalamove, the leading on-demand delivery platform, is encouraging Lalamove users in Asia and Latin America to ‘Make a Pawfect Move’ and spread the love for pets in need, by leveraging Deliver Care, Lalamove’s CSR programme dedicated to empower local communities. Lalamove encourages users to donate accumulated LalaPoints from orders they made, while the regional teams rolled out further activations, with the goal to better the lives of rescued pets.
Lalamove ‘Makes a Pawfect Move’ Globally to Support Rescued Pets
Lalamove users can now send their love to furry friends in need by registering as members of Lalamove Rewards and donate their accumulated LalaPoints with every completed order. The donated points will be used to support the operations of 10 partner animal shelters across the region, from pet food, veterinary appointments to shelter maintenance.
"With the pet economy in full bloom, Lalamove has been supporting different facets of pets lives – from the delivery of their daily essentials, to pet events, and their transportation in some markets," said Kristie Cheung, Head of Marketing Communications, Lalamove. "As an extension of Deliver Care, we are delighted to extend our team’s passion to the pet community, supporting rescued animals and their shelter ‘paw-rents’ who pour their heart into keeping the groups running.
Lalamove teams in selected markets extended their dedication to the pet community by more activation initiatives:
In Hong Kong, Lalamove will have a pet adoption event on 29th October, collaborating with Home of Homeless Dogs at Hooman by the Sea, a popular pet-centric seaside café, in West Kowloon cultural district, bringing adorable pets seeking a second chance at happiness. In Manila, the Lalamove team is donating pet supplies and offering their time to volunteer at the Pawssion Project shelter, contributing to the well-being of rescued animals. Across the oceans in Mexico City, Lalamove donated cleaning and construction products to the shelter. Thanks to their committed driver-partners and versatile range of vehicles, Lalamove successfully transported all the supplies, helping the shelter uphold a safe and hygienic environment for the animals.
Lalamove has a unique connection and love for pets, as a trustworthy delivery partner for pet merchants, communities across markets. The company has been delivering pet food and supplies daily to our furry friends and their companions with its extensive driver partner network. The idea for the campaign also emerged and came to fruition through these partnerships with local communities, among which are pet suppliers who aim to raise awareness about pet abandonment issues.
Joining hands with pet lovers, Lalamove encourages everyone to join the cause, make more deliveries and spread the word to paws-itively donate their LalaPoints to create a tail-wagging, paw-fect world for furry companions.
Founded in Hong Kong in 2013, Lalamove is an on-demand delivery platform born with a mission to empower communities by making delivery fast, simple and affordable. At the click of a button, individuals, small businesses and corporations can access a wide fleet of delivery vehicles operated by professional driver partners. Powered by technology, we seamlessly connect people, vehicles, freights and roads, moving things that matter and bringing benefits to local communities in 11 markets across Asia and Latin America.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
SHANGHAI, Oct. 10, 2023 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first subject was dosed in a phase Ib/II trial of GFH009 (a highly selective CDK9 inhibitor) treating relapsed/refractory PTCL (peripheral T-cell lymphomas) patients. Designed to enroll a total of 95 patients, this multi-center (close to 40 hospitals in China), open-label, single-arm study will include the prominent Sun Yat-Sen University Cancer Center and the First Affiliated Hospital of Zhengzhou University.
The phase I, multi-center trial of GFH009 monotherapy for relapsed/refractory hematological malignancies has completed its dose escalation portion in both China and the US. Preliminary results demonstrated favorable safety/tolerability and promising clinical efficacy of GFH009. Complete or partial responses were observed in acute myeloid leukemia and lymphoma patients; 4 PTCL patients were observed with clinical response including one in a continuous treatment for over 48 weeks. The recommended phase II dose (RP2D) has been determined to be 100 mg once per week based on all safety, pharmacokinetics, pharmacodynamics, and efficacy data.
There are approximately 100,000 newly diagnosed non-Hodgkin’s lymphoma（NHL）patients per year in China, with PTCL patients accounting for over 20% of new cases. Within the histologically and clinically heterogeneous group of PTCL, patients in most subtypes (other than ALK-positive ALCL patients) are relatively chemo-resistant and are less responsive to autologous stem cell transplants. There is significant room for improvement in terms of prognosis and overall survival rate in recurrent/refractory PTCL patients after first-line treatment. Based on current studies, the functional dependence on MCL1 and the amplification or copy-number gain of MYC observed in many PTCL cell lines are correlated to poor prognosis. Clinical trials of GFH009 demonstrated significant reduction in the expression of proto-oncogenes such as MYC, MCL1, and PCNA in patients with hematological malignancies including PTCL.
"GFH009 is GenFleet’s first clinical-stage asset for hematological malignancies in a global multi-center trial. Currently there is significant unmet medical need in recurrent/refractory PTCL; studies from GFH009 have confirmed its potential in combating the disease. Following on GFH009’s favorable safety profile and preliminary efficacy in phase I trial, we are planning to explore more studies of GFH009 monotherapy and combination therapies for global patients." stated Yu Wang, M.D., Ph.D., Chief Medical Officer of GenFleet.
GenFleet received IND approval in 2020 for the GFH009 monotherapy (NCT04588922) to proceed into phase I trial treating patients with relapsed/refractory hematological malignancies. In 2022, GenFleet and SELLAS Life Sciences Group (Nasdaq: SLS) entered into an exclusive license agreement across all therapeutic and diagnostic uses. Conducted by SELLAS, the phase IIa clinical trial of SLS009 (GFH009) with venetoclax and azacitidine is ongoing in the US treating r/r AML patients.
References:
1. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments, 2023, Cancer Biology & Therapy 2. Current status and progress of lymphoma management in China, 2018, International Journal of Hematology 3. SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia, 2023 4. VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule, 2021, Blood
About CDK9 and GFH009
As a family of serine & threonine kinases, the cyclin-dependent kinase (CDK) family plays an important role in cell cycle regulation and transcription; CDK9 activity is inversely correlated with the overall survival rate of patients with multiple tumors. Data from phase I trial and the preclinical research of GFH009 were posted at the 2002 Annual Meeting of the American Society of Hematology. GFH009 monotherapy is well tolerated with preliminary clinical activity in patients with relapsed/ refractory lymphomas and an AML patient observed with complete remission (with no minimal residual disease) lasting for over 8 months.
According to preclinical research, GFH009 reduces the expression of downstream oncogenes required for rapid cellular division and protein expression through specific inhibition of CDK9. With more than 100 times selectivity over other CDK subtypes, this depletion via GFH009 inhibition of CDK9 likely deprives oncogene-addicted cancer cells of crucial survival signals, leading to senescence and death. GFH009 also exhibits strong anti-proliferative activities in multiple human cell lines, effectively inhibits the growth of tumor in various xenograft models and significantly improves survival of tumor bearing animals.
About PTCL (peripheral T-cell lymphomas)
The incidence of PTCL in Asia is substantially higher compared with western countries. The most common PTCL subtypes in China include NK/T-cell lymphoma (NKTCL), PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and anaplastic large cell lymphoma (ALCL).
Currently, CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) or CHOP with etoposide remain the most commonly used first-line treatment for PTCL. Autologous stem cell transplantation (AUTO-HSCT) may follow as a consolidation therapy for eligible patients. Based on retrospective studies, ALK-positive ALCL patients have the most favorable prognosis after applying CHOP-based regimens. However, the prognosis of relapsed/refractory PTCL patients was poor, and the median overall survival was less than 6 months. In recent years, the development of targeted drugs provided new options for patients with relapsed and refractory PTCL.
About GenFleet Therapeutics
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies, is dedicated to serving significant global unmet medical needs in oncology and immunology. Based on the deep understanding of disease biology and translational medicine, GenFleet’s proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and global IP.
Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates – both small molecules and biologics. Its pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China (including Taiwan region), the United States, Europe and Australia. To date, GenFleet has over 5 clinical studies encompassing IND stage to phase II studies and completed co-development partnerships with numerous publicly listed companies worldwide.
GenFleet is expected to progress additional programs into the clinic, as well as transition from a clinical stage biotech company into a commercial stage biopharmaceutical company in the next 3-5 years.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
A fantastic opportunity to meet global business leaders and explore Hong Kong’s booming startup scene across the city
HONG KONG SAR – Media OutReach – 10 October 2023 – The annual StartmeupHK Festival returns to Hong Kong on 8-17 November following the monumental success in the past years. Curated by Invest Hong Kong (InvestHK) and guided by the theme A Future Unlimited, the StartmeupHK Festival 2023 will explore the latest topics around web3, healthtech, proptech, greentech, GameFi, and much more. As the leading startup event in Asia, the festival is expected to host more than 20,000 startups, investors and tech enthusiasts representing over 100 countries and regions this year.
InvestHK and event partners come together for the StartmeupHK Festival 2023 preview.
Featuring eight main events and an array of community events, what sets this year’s Festival apart is its inclusion of captivating activities in multiple locations across Hong Kong, with speakers ranging from global business leaders to some of the world’s most innovative entrepreneurs. The Festival will also host a lineup of interactive activities like pitching competitions, startup-investor matching, tech demos, job fair and networking events. What’s more, the Festival will feature a satellite event in Bangkok on 15 – 16 November, bringing together global senior executives and innovation experts to discuss corporate strategies for fostering innovation and growth.
Dr Jimmy Chiang, Acting Director-General of Investment Promotion of InvestHK said, “I am thrilled to witness the triumphant return of this remarkable event as it reaffirms Hong Kong’s leading position as a thriving hub for innovation and startup success. As one of the most vibrant cities in Asia’, Hong Kong is always an ideal place to conduct business. And it comes as no surprise that Hong Kong is a thriving hub for startups in Asia, having groomed more than 10 unicorns over the years, and home to a rapidly growing number of startups in areas as diverse as fintech, retail tech, healthtech, Internet of Things (IoT), proptech and more.”
He added, “While the local startup ecosystem is supported by a strong network of incubators and accelerators, a pool of experienced angels and venture capitalists, and a welcoming community of startups knit together by a multitude of networking events, the Hong Kong Special Administrative Region Government remains committed to supporting the growth and success of startups with increased fundings for investments in innovation and technology, to enhance research and development efforts and help more tech startups with potential. Our goal is to make Hong Kong an ideal launchpad to get startups off the ground.”
Jayne Chan, Head of StartmeupHK said, “The StartmeupHK Festival 2023 marks a significant milestone as it embraces the long-awaited opportunity for in-person interactions, and we expect this year’s Festival to be bigger and more exciting than ever. With multiple exciting events scattered across various locations in Hong Kong, including at the iconic Ocean Park and Tsim Sha Tsui waterfront, this year’s Festival is set to create a dynamic and immersive experience for all participants.”
She continued, “In addition to a wide array of the most cutting-edge topics, the Festival also offers community events to promote collaboration within the startup community. We have also curated networking events to foster deeper connections. I am excited about what this year’s Festival has in store for everyone.”
Main events
Day 1 (8 Nov) – As the opening event of the StartmeupHK Festival 2023, Explore the Innovation Ocean by Jumpstart will be held in Ocean Park Hong Kong featuring three concurrent tracks. Key sessions include engaging speakers and panels on Web3, artificial intelligence (AI), and metaverses, “Shark Tank”-style pitch competition for startups and students, and a relationship track focused on networking opportunities and booths. One of the highlights of the event will be investor matching on the Ferris Wheel.
Day 2 (9 Nov) – Hosted by Brinc, the Asia Health Innovation Summit 2023 will be held in The ParkLane – A Pullman Hotel and bring together Asia’s health ecosystem of startups, professionals, and investors to exchange knowledge, inspire one another, and help drive innovation. Key sessions will cover topics such as AI’s impact on healthcare, transforming the healthcare workforce, achieving successful healthcare innovation, and more.
Day 3 (10 Nov) – Pegasus Tech Ventures will be gathering the CEOs of the world’s leading companies, venture capitalists, large corporations, and world-renowned companies at the Startup World Cup (SWC) Asia Finale 2023 hosted at Hong Kong Science and Technology Park. The winner will not only receive a prize but also earn the opportunity to travel to San Francisco, the United States, to compete for the global championship at SWC Grand Finale, where an even larger prize awaits.
Day 4 (13 Nov) – Organised by Eureka Nova, 1.5°C Summit – The Defining Decade for Impact with Tech to be held in K11 ATELIER King’s Road is a one-of-a-kind tech summit on climate change focused on the actions needed to be taken to drastically reduce emissions before the next decade. Leading experts, entrepreneurs and stakeholders will attend the event with the goal of reducing the impact of climate change. Together, they will share their insights on how technology can transform and create a more sustainable future.
Day 5 (14 Nov) – All worlds collide at Real Estate Beyond 2023, a one-day event held in New World Millennium Hong Kong Hotel presented by Asia PropTech. The programme is designed for business and technology leaders and will emphasise knowledge sharing through insightful keynotes, panels, and small group discussions. The exhibition will showcase real estate use cases in AI, environmental, social and governance, nanotech, construction, customer relationship management, data analytics, operational efficiency, and capital markets.
Day 6 (15 Nov) – For a second year in a row, Game On! 2023, hosted by MaGESpire, will celebrate the essence of gaming, art, music, and entertainment (GAME) industries. This two-day event will gather passionate gamers, artists, developers, investors, and fans at Cyberport in a true-to-spirit gamified environment. Also kicking off on Day 6 is St. Gallen Symposium Hong Kong-Greater Bay Area Forum 2023. Under the theme “Confronting Scarcity”, this event will bring together over 150 businesses, tech startups and investment and family office leaders from Hong Kong, the Guangdong-Hong Kong-MacaoGreater Bay Area (GBA) and Europe. The thought-provoking discussions will take place at the Credit Suisse Auditorium.
Day 7 – 8 (16 – 17 Nov) – Check out JUMPSTARTER 2023 Techby The Harbour, the grand finale of the global pitching competition organised by Alibaba Entrepreneurs Fund (AEF), to take place at Tsim Sha Tsui Harbourfront. Besides the Final Pitch where innovative startups present their groundbreaking ideas and solutions, another notable highlight of the event is StartMeetUp, an exclusive business matching aimed at connecting startups with potential partners and investors.
Community events
StartmeupHK Festival 2023 will host a series of community events around Hong Kong that attendees can join to explore new ideas and meet new people.
LOUDER Connect, organised by LOUDER Global to be held on 9 Nov at Runnovation in Wanchai, will focus on identifying the reasons behind funding disparities faced by women-led businesses, exploring whether these are due to inherent business challenges, gender-biased investment culture, or other factors.
Join Undivided Ventures in an “Undivided Building Impact” x StartmeupHK event. The event, to be held on 14 Nov at the Executive Centre, will showcase four early-stage businesses, along with a panel discussion with leading experts in the industry to demonstrate that sustainable businesses and innovations in the built environment can not only have a positive environment impact for real estate owners and operators, but also be accretive to the value of their assets and their bottom line.
Last but not least, the Future of Work Unconference will be hosted by CoCoon in CoCoon Hong Kong, Causeway Bay.As technologies such as AI become more and more prominent in our day to day lives, the conference will take a deep look into what the future of work holds for everyone.
Hashtag: #smuhkfest2023 #startmeuphk #investhk
The issuer is solely responsible for the content of this announcement.
About Invest Hong Kong
Invest Hong Kong (InvestHK) is the department of the Government of the Hong Kong Special Administrative Region (HKSAR) responsible for attracting foreign direct investment and supporting overseas and mainland businesses to set up and expand in Hong Kong. It offers free advice and services to support companies from the planning stage right through to the launch and expansion of their business. For more information, please visit www.investhk.gov.hk.
About StartmeupHK
StartmeupHK is an initiative by InvestHK aimed at helping founders of innovative and scalable startups from overseas to set up or expand in Hong Kong. Our services include providing information about the startup ecosystem here in Hong Kong, connecting people to the startup community, hosting startup events and helping to foster a positive environment for startups to thrive. Find out more at www.startmeup.hk, our one-stop portal to Hong Kong’s startup ecosystem. For enquiries, please contact us at [email protected].
This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.
www.investhk.gov.hk
